Ahp14994
Capecitabine Tablet, Film Coated
Product Images NDC 60687-149
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 60687-149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Carton
Capecitabine is a cytotoxic agent available in 20 tablets per container. Its usual dosage is indicated in the package insert and the tablets should not be crushed or cut. It must be stored between 20°C to 25°C and should be kept safe from children. The drug is manufactured by Teva Pharmaceuticals USA, Inc. It's packaged and distributed by American Health Packaging located in Columbus, Ohio. The NDC code for this product is 60687-149-94.*
Cockroft And Gault Equation
This text appears to be a formula that calculates creatinine clearance for males based on age, body weight, and serum creatinine levels. It is not clear what units the result of the formula will be in.*
Figure 1
The text appears to be a survival analysis report, comparing the effectiveness of two treatments: 5-FU + LEUCOVORIN and CAPECITABINE. The results are presented as survival percentages at different points in time since randomization, ranging from 0.04 to 1.04. The data includes the number of participants at risk, the months since randomization, and the treatment group (either 5-FU + LEUCOVORIN or CAPECITABINE) at each time point.*
Figure 2
This appears to be a chart or graph, showing survival rates over time for two treatment groups: 5-FU + LEUCOVORIN and CAPECITABINE. The x-axis measures time in months, while the y-axis measures survival rate as a percentage. However, without additional context or labels, it is difficult to understand the data in more detail.*
Figure 3
This text seems to be a graphical representation of a chemotherapy regimen study. It includes information in regards to the probability estimation of the effectiveness of a chemotherapy regimen named "5-FU + Leucovorin (Mayo Regimen)" versus another one called "Capecitabine". Unfortunately, without further context and clear labels, it is not possible to determine a precise conclusion.*
Figure 4
This appears to be a table of values related to dosage and time for a medical treatment. The treatment involves the drugs Docetaxel and Capecitabine administered at specific dosages and intervals. There are also probability values listed for each interval time. It is likely that this table is part of a larger medical document or study, but without further context it is difficult to determine its exact purpose.*
Figure 5
This appears to be a table showing the Estimated Probability of something with the combination of Docetaxel and Capecitabine at different doses over time. The table shows estimated probabilities from 0 to 1 in increments of 0.1 for the specific treatment combination. The dosage and frequency of Docetaxel and Capecitabine are also provided in the table. The horizontal axis represents the timeline in days.*
Metabolic Pathway
This appears to be a chemical structure diagram of a molecule and its enzymatic reactions. The molecule is likely Capecitabine, which undergoes conversion to 5-DFCR, and then to 5"-DFUR with the help of the enzyme cytidine deaminase. Another enzyme called dThdPase may also be involved, possibly in the conversion of 5"-DFUR to 5-FU. The text does not provide any further information beyond this.*
Structure
Structural Formula (Image 01)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
